Jane Street
AVIR icon

Jane Street’s Atea Pharmaceuticals AVIR Stock Holding History

Jane Street’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,900
Closed -$86.7K – 11090
2025
Q3 		$86.7K Buy
+29,900
New +$102K ﹤0.01% 10190
2022
Q3 		– Sell
-11,500
Closed -$82K – 9668
2022
Q2 		$82K Sell
11,500
-175,400
-94% -$1.2M ﹤0.01% 8745
2022
Q1 		$1.35M Sell
186,900
-220,800
-54% -$1.5M ﹤0.01% 5498
2021
Q4 		$3.65M Buy
407,700
+387,300
+1,899% +$6.04M ﹤0.01% 3367
2021
Q3 		$715K Buy
20,400
+1,000
+5% +$27.7K ﹤0.01% 6599
2021
Q2 		$417K Buy
+19,400
New +$583K ﹤0.01% 7579

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street's AVIR Position: Q2 2026 in Review

Jane Street sold out of Atea Pharmaceuticals (AVIR) in Q2 2026, closing a stake of 418,296 shares — an estimated $2.25M sold.

Jane Street first reported a position in AVIR in Q2 2021 and held it in 20 quarters. The position peaked at $2.61M in Q3 2021. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Jane Street reported no remaining Atea Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 418,296 Atea Pharmaceuticals shares in Q2 2026, an estimated $2.25M.
  • Jane Street first reported a position in Atea Pharmaceuticals in Q2 2021 and held it in 20 quarters.
  • Jane Street's Atea Pharmaceuticals position peaked at $2.61M in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.